CUFinder

Qingchun Jin

Qingchun Jin

Harvard University

H-index: 5

North America-United States

Contact Qingchun Jin

About Qingchun Jin

Qingchun Jin, With an exceptional h-index of 5 and a recent h-index of 5 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Biostatistics, Clinical trial, Biomarkers.

His recent articles reflect a diverse array of research interests and contributions to the field:

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Axillary nodal response to neoadjuvant T-DM1 combined with pertuzumab in a prospective phase II multi-institution clinical trial

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance …

Mo1129 PHASE 3 BIOMARKER STUDY FOR HCC SURVEILLANCE USING A NOVEL HES V2. 0 ALGORITHM. A PROSPECTIVE COLLECTION WITH RETROSPECTIVE BLINDED EVALUATION

Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and …

Qingchun Jin Information

University

Position

Dana-Farber Cancer Institute

Citations(all)

223

Citations(since 2020)

221

Cited By

0

hIndex(all)

5

hIndex(since 2020)

5

i10Index(all)

4

i10Index(since 2020)

4

Email

University Profile Page

Google Scholar

Qingchun Jin Skills & Research Interests

Biostatistics

Clinical trial

Biomarkers

Top articles of Qingchun Jin

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer

NPJ Breast Cancer

2024/4/16

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Filipa Lynce
Filipa Lynce

H-Index: 13

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial

Nature Communications

2024/3/19

Jorge Gómez Tejeda Zañudo
Jorge Gómez Tejeda Zañudo

H-Index: 12

Romualdo Barroso-Sousa
Romualdo Barroso-Sousa

H-Index: 19

Esha Jain
Esha Jain

H-Index: 9

Qingchun Jin
Qingchun Jin

H-Index: 0

Tianyu Li
Tianyu Li

H-Index: 0

Jorge E Buendia-Buendia
Jorge E Buendia-Buendia

H-Index: 6

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Nikhil Wagle
Nikhil Wagle

H-Index: 42

Axillary nodal response to neoadjuvant T-DM1 combined with pertuzumab in a prospective phase II multi-institution clinical trial

Journal of the American College of Surgeons

2024/3/1

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer

Journal of Clinical Oncology

2024/1/8

Qingchun Jin
Qingchun Jin

H-Index: 0

Alex Wilson
Alex Wilson

H-Index: 6

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Peter G Miller
Peter G Miller

H-Index: 31

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Annals of Oncology

2023/10/1

Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor–Positive Breast Cancer: Implications for Guidance …

JCO Oncology Practice

2023/8

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Mo1129 PHASE 3 BIOMARKER STUDY FOR HCC SURVEILLANCE USING A NOVEL HES V2. 0 ALGORITHM. A PROSPECTIVE COLLECTION WITH RETROSPECTIVE BLINDED EVALUATION

Gastroenterology

2023/5/1

Hashem B El-Serag
Hashem B El-Serag

H-Index: 91

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Qingchun Jin
Qingchun Jin

H-Index: 0

Abstract P2-01-02: Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and …

Cancer Research

2023/3/1

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Judy Garber
Judy Garber

H-Index: 52

Filipa Lynce
Filipa Lynce

H-Index: 13

Abstract P5-14-03: Clonal hematopoiesis of indeterminate potential after (neo) adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective …

Cancer Research

2023/3/1

Qingchun Jin
Qingchun Jin

H-Index: 0

Alex Wilson
Alex Wilson

H-Index: 6

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Peter Miller
Peter Miller

H-Index: 18

Judy Garber
Judy Garber

H-Index: 52

Circulating progenitor cells and outcomes in patients with coronary artery disease

International Journal of Cardiology

2023/2/15

Qingchun Jin
Qingchun Jin

H-Index: 0

Anurag Mehta
Anurag Mehta

H-Index: 11

Chang Liu
Chang Liu

H-Index: 7

Aditi Nayak
Aditi Nayak

H-Index: 7

Kiran Ejaz
Kiran Ejaz

H-Index: 14

Ananya Hooda
Ananya Hooda

H-Index: 2

Ali Mokhtari
Ali Mokhtari

H-Index: 1

Yi-An Ko
Yi-An Ko

H-Index: 21

Edmund K Waller
Edmund K Waller

H-Index: 49

Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Cancer Research

2023/10/2

Yingtian Xie
Yingtian Xie

H-Index: 7

Zsuzsanna Nagy
Zsuzsanna Nagy

H-Index: 1

Marco Campisi
Marco Campisi

H-Index: 9

Israel Cañadas
Israel Cañadas

H-Index: 14

Ying Huang
Ying Huang

H-Index: 10

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Xintao Qiu
Xintao Qiu

H-Index: 13

Jia-Ren Lin
Jia-Ren Lin

H-Index: 18

Sandro Santagata
Sandro Santagata

H-Index: 53

David Barbie
David Barbie

H-Index: 39

HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications

European Journal of Cancer

2022/10/1

Nolan Priedigkeit
Nolan Priedigkeit

H-Index: 13

Antonio Giordano
Antonio Giordano

H-Index: 50

Sarah Strauss
Sarah Strauss

H-Index: 14

Qingchun Jin
Qingchun Jin

H-Index: 0

Filipa Lynce
Filipa Lynce

H-Index: 13

206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications

Annals of Oncology

2022/9/1

Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib

EARD

2021

Luca Magnani
Luca Magnani

H-Index: 24

Massimo Dominici
Massimo Dominici

H-Index: 41

Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer

JAMA oncology

2022/8/1

Qingchun Jin
Qingchun Jin

H-Index: 0

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Svitlana Tyekucheva
Svitlana Tyekucheva

H-Index: 23

Tianyu Li
Tianyu Li

H-Index: 0

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic …

2022/7/12

67P Clinicopathologic features of breast cancer patients eligible for adjuvant abemaciclib

Annals of Oncology

2022/5/1

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Annals of Oncology

2022/5/1

Doylestown plus and GALAD demonstrate high sensitivity for HCC detection in patients with cirrhosis

Clinical Gastroenterology and Hepatology

2022/4/1

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Qingchun Jin
Qingchun Jin

H-Index: 0

GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis

Hepatology

2022/3

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Qingchun Jin
Qingchun Jin

H-Index: 0

See List of Professors in Qingchun Jin University(Harvard University)